- Home
- NDLS vs INKT Comparison
NDLS vs INKT Comparison
Compare NDLS & INKT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NDLS
- INKT
- Stock Information
- Founded
- NDLS 1995
- INKT 2017
- Country
- NDLS United States
- INKT United States
- Employees
- NDLS N/A
- INKT N/A
- Industry
- NDLS Restaurants
- INKT Medicinal Chemicals and Botanical Products
- Sector
- NDLS Consumer Discretionary
- INKT Health Care
- Exchange
- NDLS Nasdaq
- INKT Nasdaq
- Market Cap
- NDLS 32.9M
- INKT 28.8M
- IPO Year
- NDLS 2013
- INKT 2021
- Fundamental
- Price
- NDLS $0.90
- INKT $62.86
- Analyst Decision
- NDLS Strong Buy
- INKT Strong Buy
- Analyst Count
- NDLS 2
- INKT 2
- Target Price
- NDLS $3.00
- INKT $37.50
- AVG Volume (30 Days)
- NDLS 223.1K
- INKT 2.4M
- Earning Date
- NDLS 08-06-2025
- INKT 08-12-2025
- Dividend Yield
- NDLS N/A
- INKT N/A
- EPS Growth
- NDLS N/A
- INKT N/A
- EPS
- NDLS N/A
- INKT N/A
- Revenue
- NDLS $495,670,000.00
- INKT N/A
- Revenue This Year
- NDLS $5.37
- INKT N/A
- Revenue Next Year
- NDLS $0.68
- INKT N/A
- P/E Ratio
- NDLS N/A
- INKT N/A
- Revenue Growth
- NDLS N/A
- INKT N/A
- 52 Week Low
- NDLS $0.55
- INKT $4.56
- 52 Week High
- NDLS $1.83
- INKT $76.00
- Technical
- Relative Strength Index (RSI)
- NDLS 61.53
- INKT 57.39
- Support Level
- NDLS $0.66
- INKT $6.80
- Resistance Level
- NDLS $0.82
- INKT $7.88
- Average True Range (ATR)
- NDLS 0.08
- INKT 0.40
- MACD
- NDLS 0.02
- INKT 0.02
- Stochastic Oscillator
- NDLS 93.68
- INKT 58.86
About NDLS Noodles & Company
Noodles & Co is a restaurant concept offering lunch and dinner within the fast-casual segment of the restaurant industry. The company's menu includes a variety of cooked-to-order dishes, including noodles and pasta, soups, salads and appetizers. The company also provides dining, pick-up and delivery services.
About INKT MiNK Therapeutics Inc.
MiNK Therapeutics Inc is a clinical-stage biopharmaceutical company pioneering the discovery, development, and commercialization of allogeneic invariant natural killer T (iNKT) cell therapies to treat cancer and other immune-mediated diseases. The company is advancing a pipeline of both native and next generation engineered iNKT programs, with a platform designed to facilitate scalable and reproducible manufacturing for off-the-shelf delivery.